KR100275593B1 - 경피 침투 강화제로써 트리아세틴 - Google Patents

경피 침투 강화제로써 트리아세틴 Download PDF

Info

Publication number
KR100275593B1
KR100275593B1 KR1019970707309A KR19970707309A KR100275593B1 KR 100275593 B1 KR100275593 B1 KR 100275593B1 KR 1019970707309 A KR1019970707309 A KR 1019970707309A KR 19970707309 A KR19970707309 A KR 19970707309A KR 100275593 B1 KR100275593 B1 KR 100275593B1
Authority
KR
South Korea
Prior art keywords
triacetin
drug
skin
adhesive
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019970707309A
Other languages
English (en)
Korean (ko)
Other versions
KR19990007786A (ko
Inventor
다니 쿠안
닌아드 에이. 데쉽판다이
시리나바신 벤카테쉬와란
찰스 디. 에버트
Original Assignee
에버트 챨스 디
테라테크인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23704623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100275593(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에버트 챨스 디, 테라테크인코포레이티드 filed Critical 에버트 챨스 디
Publication of KR19990007786A publication Critical patent/KR19990007786A/ko
Application granted granted Critical
Publication of KR100275593B1 publication Critical patent/KR100275593B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019970707309A 1995-04-26 1996-04-08 경피 침투 강화제로써 트리아세틴 Expired - Lifetime KR100275593B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/429,757 US5601839A (en) 1995-04-26 1995-04-26 Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US8/429,757 1995-04-26
US8/429757 1995-04-26

Publications (2)

Publication Number Publication Date
KR19990007786A KR19990007786A (ko) 1999-01-25
KR100275593B1 true KR100275593B1 (ko) 2000-12-15

Family

ID=23704623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970707309A Expired - Lifetime KR100275593B1 (ko) 1995-04-26 1996-04-08 경피 침투 강화제로써 트리아세틴

Country Status (18)

Country Link
US (2) US5601839A (enExample)
EP (1) EP0871420B1 (enExample)
JP (2) JP3228341B2 (enExample)
KR (1) KR100275593B1 (enExample)
CN (3) CN100374161C (enExample)
AR (1) AR001721A1 (enExample)
AT (1) ATE205694T1 (enExample)
AU (1) AU696777B2 (enExample)
CA (1) CA2217888C (enExample)
DE (2) DE122005000013I1 (enExample)
DK (1) DK0871420T3 (enExample)
ES (1) ES2163012T3 (enExample)
FR (1) FR05C0008I2 (enExample)
NL (1) NL300200I1 (enExample)
NZ (1) NZ306249A (enExample)
PT (1) PT871420E (enExample)
WO (1) WO1996033678A1 (enExample)
ZA (1) ZA963229B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975677B1 (ko) 2017-11-20 2019-05-07 양진석 환편기용 보풀 제거장치
KR20200047437A (ko) 2018-10-26 2020-05-07 경상대학교산학협력단 아세틴 화합물의 생물학적 제조 방법

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
ATE322272T1 (de) * 1996-07-15 2006-04-15 Alza Corp Neue formulierungen zur transdermale verabreichung von fluoxetin
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
EP0942697A1 (en) * 1996-10-30 1999-09-22 THERATECH, INC. (a Delaware Corporation) Fatty acid esters of lactic acid salts as permeation enhancers
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
DE19706824C1 (de) * 1997-02-21 1998-03-26 Lohmann Therapie Syst Lts Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
BR9814014B1 (pt) * 1997-11-10 2014-10-07 Strakan Int Ltd Composição para aplicação tópica tendo propriedades de melhora da penetração
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
EP1459741A1 (en) * 1997-12-15 2004-09-22 Noven Pharmaceuticals, Inc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate
US6727401B1 (en) * 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
DE19812413C1 (de) * 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU3536799A (en) * 1999-04-26 2000-11-10 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
AU6403600A (en) * 1999-06-10 2001-01-02 Sepracor, Inc. Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
AU769079B2 (en) 1999-06-25 2004-01-15 Durham Pharmaceuticals Ltd. Topical formulations comprising skin penetration agents and the use thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US20010049546A1 (en) * 2000-02-08 2001-12-06 Israel Dvoretzky Multi-purpose drug and heat therapy treatment system
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
MXPA02010542A (es) * 2000-04-26 2003-10-14 Watson Pharmaceuticals Inc Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
WO2002064162A2 (en) 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
CA2446619C (en) * 2001-05-11 2011-04-26 Elan Corporation, Plc Permeation enhancers
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
JP4295467B2 (ja) * 2002-04-12 2009-07-15 日東電工株式会社 貼付剤およびその製造方法
KR100469995B1 (ko) * 2002-05-20 2005-02-05 안국약품 주식회사 천식치료제를 함유한 매트릭스형 패취
JP4323138B2 (ja) * 2002-06-05 2009-09-02 日東電工株式会社 経皮吸収型製剤およびその製造方法
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US20040197397A1 (en) * 2002-08-30 2004-10-07 Watson Pharmaceuticals, Inc. Drug delivery system for treatment of urinary incontinence
DE10251256A1 (de) * 2002-11-04 2004-05-13 Novosis Ag Transdermales Wirkstoffabgabesystem für Oxybutynin
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4898431B2 (ja) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US8173155B2 (en) * 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
CN101146523B (zh) 2004-10-21 2010-12-29 杜雷科特公司 透皮给药系统
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
JP5037831B2 (ja) * 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
CA2643037C (en) * 2006-02-27 2014-08-05 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
WO2007143675A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE602007009574D1 (de) * 2006-12-28 2010-11-11 Kaken Pharma Co Ltd Gelzusammensetzung zur behandlung von mykose
NZ552816A (en) * 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
CA2679316C (en) 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US10183001B1 (en) * 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US20100278935A1 (en) * 2007-07-30 2010-11-04 Stacey William C Immune System Modulator Formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
CN101896175B (zh) * 2007-12-12 2013-03-13 帝国制药株式会社 含有环氧洛芬的水性贴剂
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
US8404255B2 (en) * 2008-07-29 2013-03-26 Matt Gibson System and method for transdermal drug delivery
ES2400210T3 (es) 2008-10-02 2013-04-08 Mylan Inc. Método para preparar un laminado de adhesivo multicapa
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
BR112012011334A2 (pt) * 2009-10-21 2020-08-25 Teikoku Seiyaku Co., Ltd. formulação transdermicamente absorvível contendo donepezil
CN102740890B (zh) 2009-12-15 2015-05-13 帝国制药株式会社 含碱性消炎镇痛药的经皮吸收制剂
CN103491778B (zh) 2010-04-13 2017-05-31 雷尔玛达治疗股份有限公司 1‑甲基‑n‑(2，6‑二甲苯基)‑2‑哌啶甲酰胺的皮肤用药物组合物及其使用方法
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
FR2972923B1 (fr) * 2011-03-25 2013-08-23 Urgo Lab Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
MX368747B (es) 2011-05-10 2019-10-14 Itochu Chemical Frontier Corp Parche no acuoso de lidocaína y un agente de disolución que comprende un ácido orgánico y un polialcohol que están contenidos en un emplaste para usarse en el tratamiento de dolor muscular a través de la piel.
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
SI2823815T1 (sl) 2011-09-27 2018-09-28 Itochu Chemical Frontier Corporation Ne-vodni obliž
US20140271796A1 (en) * 2011-10-26 2014-09-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation
US20130266643A1 (en) * 2012-04-10 2013-10-10 Hpo Life Sciences, Inc. Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis
WO2014034929A1 (ja) * 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
US9072682B2 (en) 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
CN103919754B (zh) * 2013-01-15 2018-11-06 江苏康倍得药业股份有限公司 奥昔布宁药物组合物及其应用
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AR095258A1 (es) * 2013-03-14 2015-09-30 Noven Pharma Composiciones transdérmicas de metilfenidato con adhesivos a base de goma
WO2015139847A1 (en) * 2014-03-21 2015-09-24 Chironwells Gmbh 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament
EP3242659A4 (en) 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
WO2018200387A1 (en) 2017-04-24 2018-11-01 Chase Therapeutics Corporation Compositions and method for treating depression
JP2019034905A (ja) * 2017-08-17 2019-03-07 コスメディ製薬株式会社 デヒドロ酢酸含有経皮吸収製剤
WO2019089523A1 (en) * 2017-10-30 2019-05-09 Theracaine Llc Hydrophobic acid addition salts and pharmaceutical formulations thereof
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
JP2022122784A (ja) 2021-02-10 2022-08-23 コスメディ製薬株式会社 酸化防止剤含有経皮吸収製剤
KR20230026232A (ko) 2021-08-17 2023-02-24 신신제약 주식회사 옥시부티닌을 함유하는 경피흡수제제
CN113749968A (zh) * 2021-10-26 2021-12-07 奥易生物科技(杭州)有限公司 一种快速透皮吸收的化妆品及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466926A (en) * 1892-01-12 Advertising device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336262A (en) * 1973-02-23 1982-06-22 Fisons Ltd. Pour-on veterinary anthelmintic
WO1986000814A1 (en) * 1984-07-24 1986-02-13 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4666926A (en) * 1986-02-27 1987-05-19 Warner-Lambert Company Transdermal formulations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
JPH0676327B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
US4857313A (en) * 1987-05-28 1989-08-15 Warner-Lambert Company Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
JP2526256B2 (ja) * 1987-11-17 1996-08-21 清水建設株式会社 構造物の振動抑制装置
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
DE3943519A1 (de) * 1989-04-27 1991-01-17 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
US5496819A (en) * 1991-11-15 1996-03-05 Ss Pharmaceutical Co., Ltd. Antiphlogistic-analgesic plaster comprising triacetin and piroxicam
JP3130350B2 (ja) * 1991-11-28 2001-01-31 積水化学工業株式会社 経皮吸収製剤
TW224048B (enExample) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
WO1993025168A1 (en) * 1992-06-11 1993-12-23 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
JPH08245377A (ja) * 1995-03-15 1996-09-24 Yamanouchi Pharmaceut Co Ltd 経皮吸収用製剤
JPH09309783A (ja) * 1996-05-20 1997-12-02 Chisso Corp 改良された土中崩壊型被覆粒状肥料

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466926A (en) * 1892-01-12 Advertising device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975677B1 (ko) 2017-11-20 2019-05-07 양진석 환편기용 보풀 제거장치
KR20200047437A (ko) 2018-10-26 2020-05-07 경상대학교산학협력단 아세틴 화합물의 생물학적 제조 방법

Also Published As

Publication number Publication date
AU5446796A (en) 1996-11-18
EP0871420B1 (en) 2001-09-19
CN1714867A (zh) 2006-01-04
KR19990007786A (ko) 1999-01-25
ES2163012T3 (es) 2002-01-16
AR001721A1 (es) 1997-11-26
CN1182358A (zh) 1998-05-20
NZ306249A (en) 2000-03-27
CA2217888A1 (en) 1996-10-31
EP0871420A4 (enExample) 1998-11-11
FR05C0008I2 (enExample) 2007-05-25
DE69615399T2 (de) 2003-01-30
DE69615399D1 (de) 2001-10-25
MX9707868A (es) 1997-11-29
NL300200I1 (nl) 2005-09-01
JP2001039865A (ja) 2001-02-13
DE122005000013I1 (de) 2005-06-23
HK1084320A1 (zh) 2006-07-28
CN1507918A (zh) 2004-06-30
DK0871420T3 (da) 2002-01-21
US5601839A (en) 1997-02-11
ATE205694T1 (de) 2001-10-15
JP4511691B2 (ja) 2010-07-28
ZA963229B (en) 1997-01-28
PT871420E (pt) 2002-03-28
EP0871420A1 (en) 1998-10-21
JP3228341B2 (ja) 2001-11-12
FR05C0008I1 (enExample) 2005-04-29
CN100374161C (zh) 2008-03-12
CN1143688C (zh) 2004-03-31
JPH10507199A (ja) 1998-07-14
US5834010A (en) 1998-11-10
WO1996033678A1 (en) 1996-10-31
CA2217888C (en) 2001-08-28
AU696777B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
KR100275593B1 (ko) 경피 침투 강화제로써 트리아세틴
AU677206B2 (en) The use of glycerin in moderating transdermal drug delivery
JP2550441B2 (ja) 皮膚透過性促進組成物
EP1163902B1 (en) Transdermal preparation containing hydrophilic or salt-form drug
CA2277367A1 (en) Transdermal therapeutic system
KR20000068029A (ko) 제약학적 물질염을 경피 수송하기 위한 압력 감응성 접착제
PT96059B (pt) Sistema de camada unica para a administracao de um medicamento por via transdermica
WO1992020377A1 (en) Skin permeation enhancer compositions using glycerol monolinoleate
TW201431572A (zh) 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法
PT1589973E (pt) FORMULAÆO E MéTODOS PARA O TRATAMENTO DE TROMBOCITEMIA
WO2001091724A2 (en) Transdermal delivery of lasofoxifene
JP3980634B2 (ja) 活性物質モルフィン−６−グルクロニドを含む全身的経皮投与用医薬組成物
AU628660B2 (en) Transdermal delivery (+)(2s,3s)-3-acetoxy-8-chloro-5- (2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl) -1,5-benzothiazepin-4-(5h)-one
EP1711170B1 (en) Transdermal delivery device for dihydropyridine type calcium antagonists containing two fatty acids
KR100439659B1 (ko) 툴로부테롤을 함유하는 경피흡수용 패취제
HK1084320B (en) Triacetin as a transdermal penetration enhancer
MXPA97007868A (es) La triacetina como incrementador de penetraciontransdermica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971016

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980108

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991027

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000105

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20000406

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20000105

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20000630

Appeal identifier: 2000101000741

Request date: 20000406

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20000504

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20000406

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19991220

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19980108

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20000630

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20000530

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20000922

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20000923

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20030915

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20040916

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20050916

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20060919

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20070918

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20080922

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20090918

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20100907

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20110906

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20120906

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20120906

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20130910

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20130910

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20150908

Year of fee payment: 16

PR1001 Payment of annual fee

Payment date: 20150908

Start annual number: 16

End annual number: 16

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20161008

Termination category: Expiration of duration